Blood Cancer Care Faces Access and Affordability Challenges for CAR T-cell Therapy
The delivery of blood cancer care, particularly Chimeric Antigen Receptor (CAR) T-cell therapy, is encountering significant hurdles related to patient access, affordability, and the coordination between various healthcare stakeholders. Despite the innovative potential of CAR T-cell therapy, patients often face difficulties in receiving treatment due to factors such as lower household income and extended travel times, as highlighted in an observational study by Ahmed and colleagues. The current system struggles to align incentives among manufacturers, treatment centers, health plans, and community oncology practices, leading to disagreements on funding and service delivery. While manufacturers seek sales and centers aim for business, health plans face higher short-term costs, creating a complex environment where patient access can be compromised. The discussion emphasizes the need for improved collaboration and financial models to ensure that patients can access these critical therapies.
